Ionis Pharmaceuticals Stock Slides 37% Over 7 Straight Down Days
A biotechnology firm’s persistent stock decline prompts a closer look at the numbers behind the momentum.
Ionis Pharmaceuticals (IONS) stock has now moved LOWER for 7 consecutive trading days, a cumulative loss of 36.7%. That streak has erased about $5.2 billion from the company’s market value, which now stands at about $9.0 billion.
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States.
How The Streak Stacks Up Against The S&P 500
Here is how IONS stock stacks up against the S&P 500 over the streak and the periods around it:
| Return Period | IONS | S&P 500 |
|---|---|---|
| 1D | -0.1% | -0.5% |
| 7D (Current Streak) | -36.7% | 0.4% |
| 1M (21D) | -26.1% | -0.3% |
| 3M (63D) | -28.9% | 7.3% |
| YTD 2026 | -30.9% | 10.1% |
| 2025 | 126.3% | 16.4% |
| 2024 | -30.9% | 23.3% |
| 2023 | 33.9% | 24.2% |
What do the fundamentals suggest about this slide?
This decline is specific to the company, not the broader market. Over the same 7 trading days, the S&P 500 returned +0.4%. While such streaks are not unique, 18 of the S&P 500 stocks are currently on losing streaks of 3 days or more, and the underlying financials show areas of strain.
Ionis’s operating margin over the last twelve months is -33.3%, a sharp contrast to the S&P 500 median of 18.4%. The market may be weighing these profitability metrics against the company’s growth.
A streak is a question, not an answer.
A multi-day move in one direction is a signal of sustained attention and momentum. It is not, by itself, an instruction to buy or sell.
The disciplined response is to treat the streak as a prompt to re-evaluate the business relative to its new price. The data on profitability and valuation provides a clear starting point for that assessment.
A slide like this always poses the same follow-up: which marked-down stocks are actually worth buying? Our Buy the Dip screen runs that test every day, flagging beaten-down names whose fundamentals still hold up.
Prefer the theme to this single name? Our ETF Scorecard shows how the biotech funds stack up. It is still a concentrated bet on that one theme, though, which is exactly the gap the portfolio below closes.
A Slide Like This Is Why Diversification Exists
Watching one stock fall day after day is the clearest lesson the market teaches about single-name risk. Whether this particular decline is an opportunity or a warning, the deeper point is the same: no one name should be able to do this to your portfolio.
The Trefis High Quality (HQ) Portfolio is built on that principle: roughly 30 businesses selected for consistent cash generation, strong margins, and resilient balance sheets, sized and rebalanced with rules. It has a track record of outpacing a benchmark that combines all major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Study the slide; spread the risk.